Taylor Morrisette

List of Publications by Citations

175 papers	10,804 citations	44 h-index	102 g-index
186 ext. papers	13,063 ext. citations	5.7 avg, IF	6.43 L-index

#	Paper	IF	Citations
175	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. *Clinical Infectious Diseases*, **2011**, 52, e18-55	11.6	1736
174	Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Circulation*, **2015**, 132, 1435-86	16.7	1479
173	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. *Clinical Infectious Diseases*, **2011**, 52, 285-92	11.6	1209
172	Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. *Clinical Infectious Diseases*, **2009**, 49, 325-7	11.6	566
171	The pharmacokinetic and pharmacodynamic properties of vancomycin. *Clinical Infectious Diseases*, **2006**, 42 Suppl 1, S35-9	11.6	483
170	Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy*, **2020**, 77, 835-864	2.2	307
169	In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 1062-6	5.9	275
168	Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*, **2009**, 29, 1275-9	5.8	207
167	Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with	5.9	166
166	A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	126
165	Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). *Journal of Clinical Microbiology*, **2008**, 46, 2950-4	9.7	120
164	Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. *Clinical Therapeutics*, **2014**, 36, 1317-33	3.5	118
163	Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.	5.9	118
162	Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. *Clinical Infectious Diseases*, **2017**, 64, 116-123	11.6	114
161	The β-Lactams Strike Back: Ceftazidime-Avibactam. *Pharmacotherapy*, **2015**, 35, 755-70	5.8	113
160	Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 66-73	5.9	98
159	A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. *Clinical Infectious Diseases*, **2018**, 67, 303-309	11.6	92

158	Community-associated methicillin-resistant Staphylococcus aureus: a review. *Pharmacotherapy*, **2005**, 25, 74-85	5.8	89
157	Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. *Drugs*, **2001**, 61, 1-7	12.1	85
156	Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2541-6	5.9	84
155	1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI). *Open Forum Infectious Diseases*, **2019**, 6, S582-S582	1	78
154	Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 3174-80	5.9	76
153	β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 1738-43	5.1	75
152	Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	72
151	Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. *Journal of Emergency Medicine*, **2015**, 48, 508-19	1.5	72
150	In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 4712-7	5.9	69
149	Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. *Clinical Infectious Diseases*, **2016**, 62, 1242-1250	11.6	64
148	Inhibition of drug metabolism by quinolone antibiotics. *Clinical Pharmacokinetics*, **1988**, 15, 194-204	6.2	62
147	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4252-4259	5.9	58
146	Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections. *Infectious Diseases and Therapy*, **2015**, 4, 245-58	6.2	57
145	Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. *Infectious Diseases and Therapy*, **2016**, 5, 1-15	6.2	55
144	Daptomycin - a novel antibiotic against Gram-positive pathogens. *Expert Opinion on Pharmacotherapy*, **2004**, 5, 2321-31	4	55
143	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Clinical Infectious Diseases*, **2020**, 71, 1361-1364	11.6	55
142	Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 152-5	5.1	54
141	Pharmacodynamics: relation to antimicrobial resistance. *American Journal of Medicine*, **2006**, 119, S37-44; discussion S62-70	2.4	53

140	Making the change to area under the curve-based vancomycin dosing. *American Journal of Health-System Pharmacy*, **2018**, 75, 1986-1995	2.2	53
139	Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	52
138	Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. *Infectious Diseases and Therapy*, **2014**, 3, 35-43	6.2	52
137	Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties. *Infectious Diseases and Therapy*, **2018**, 7, 197-217	6.2	51
136	Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence. *Pharmacotherapy*, **2017**, 37, 579-592	5.8	50
135	Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect". *Antimicrobial Agents and*	5.9	48
134	Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2978-85	5.9	47
133	Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3743-50	5.9	47
132	Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2148-54	5.1	45
131	Pharmacodynamics: relation to antimicrobial resistance. *American Journal of Infection Control*, **2006**, 34, S38-45; discussion S64-73	3.8	42
130	Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	41
129	Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. *Open Forum Infectious Diseases*, **2019**, 6, ofz522	1	41
128	Daptomycin Plus ß-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. *Clinical Infectious Diseases*, **2020**, 71, 1-10	11.6	39
127	Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5841-8	5.9	38
126	On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 2405-2416	5.1	36
125	Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 3006-10	5.1	36
124	Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3177-81	5.9	35
123	Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 311-3	5.1	34

122	Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. *Pharmacotherapy*, **2015**, 35, 935-48	5.8	33
121	β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2842-8	5.9	32
120	Resistance to antimicrobial agents: an update. *Pharmacotherapy*, **2004**, 24, 203S-15S	5.8	32
119	Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 1921-4	5.9	32
118	Ofloxacin clinical pharmacokinetics. *Clinical Pharmacokinetics*, **1992**, 22, 32-46	6.2	31
117	Perturbations of Phosphatidate Cytidylyltransferase (CdsA) Mediate Daptomycin Resistance in Streptococcus mitis/oralis by a Novel Mechanism. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	30
116	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 505-9	5.1	30
115	β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	30
114	Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 489-93	5.1	30
113	Multicenter Cohort of Patients With Methicillin-Resistant Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. *Open Forum Infectious Diseases*, **2020**, 7, ofz538	1	30
112	Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4497-503	5.9	29
111	A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2989-92	5.9	29
110	Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations. *Pharmacotherapy*, **2020**, 40, 153-168	5.8	29
109	Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 5709-14	5.9	28
108	Long-Acting Lipoglycopeptides: "Lineless Antibiotics" for Serious Infections in Persons Who Use Drugs. *Open Forum Infectious Diseases*, **2019**, 6, ofz274	1	27
107	Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1969-76	5.9	27
106	Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5716-23	5.9	27
105	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*, **2020**, 40, 363-367	5.8	26

104	Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	25
103	Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 1708-16	5.9	24
102	Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. *Open Forum Infectious Diseases*, **2020**, 7, ofaa051	1	23
101	Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. *Diagnostic Microbiology and Infectious Disease*, **2017**, 89, 61-66	2.9	22
100	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. *Clinical Infectious Diseases*, **2019**, 68, 1650-1657	11.6	22
99	Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 489-498	5.1	21
98	Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3968-75	5.9	20
97	A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii. *Infectious Diseases and Therapy*, **2014**, 3, 69-81	6.2	20
96	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Journal of the*	4.8	20
95	Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 6609-6618	5.9	19
94	Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2352-8	5.9	19
93	Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. *Diagnostic Microbiology and Infectious Disease*, **2005**, 51, 119-25	2.9	19
92	Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5529-34	5.9	18
91	Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	17
90	Evaluation of Eravacycline: A Novel Fluorocycline. *Pharmacotherapy*, **2020**, 40, 221-238	5.8	17
89	Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1584-91	5.9	16
88	Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2091-2097	4.7	16
87	Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. *Drug Discovery Today*, **2021**, 26, 31-43	8.8	16

86	Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	16
85	Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review. *Pharmacotherapy*, **2020**, 40, 469-478	5.8	15
84	Nephrotoxicity comparison of two commercially available generic vancomycin products. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5470-4	5.9	15
83	Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens. *Pharmacotherapy*, **2020**, 40, 1228-1247	5.8	15
82	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. *Infectious Diseases and Therapy*, **2020**, 9, 561-572	6.2	15
81	Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of in a Simulated Pharmacodynamic/Pharmacokinetic Model. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	14
80	Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2428-31	5.9	14
79	Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3970-5	5.9	14
78	Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs). *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 2290-2296	5.1	13
77	Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis. *Infectious Diseases and Therapy*, **2020**, 9, 325-339	6.2	13
76	Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	12
75	Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA. *Materials*, **2018**, 11,	3.5	12
74	Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	12
73	The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	12
72	Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. *Pharmacotherapy*, **2020**, 40, 648-658	5.8	11
71	Early Experience With Eravacycline for Complicated Infections. *Open Forum Infectious Diseases*, **2020**, 7, ofaa071	1	11
70	A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. *Infectious Diseases and Therapy*, **2020**, 9, 89-106	6.2	11
69	Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an Model of Simulated Endocardial Vegetations. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	11

68	Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4636-41	5.9	11
67	Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus. *Journal of Medical Microbiology*, **2008**, 57, 452-456	3.2	11
66	Antimicrobial stewardship. *Pharmacotherapy*, **2007**, 27, 131S-135S	5.8	11
65	Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. *Infectious Diseases and Therapy* , **2018**, 7, 135-146	6.2	11
64	Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide. *Pharmacotherapy*, **2019**, 39, 1077-1094	5.8	10
63	Mutations in and Correlate with Daptomycin Resistance in and. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	10
62	Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 82-86	5.1	10
61	Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus. *Diagnostic Microbiology and Infectious Disease*, **2018**, 91, 363-370	2.9	10
60	Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin. *Infectious Diseases and Therapy*, **2019**, 8, 155-170	6.2	9
59	Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	9
58	Preliminary, Real-world, Multicenter Experience With Omadacycline for Infections. *Open Forum Infectious Diseases*, **2021**, 8, ofab002	1	9
57	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. *Infectious Diseases and Therapy*, **2021**, 10, 93-113	6.2	9
56	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin. *Open Forum Infectious Diseases*, **2019**, 6, ofz079	1	8
55	Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury. *Infectious Diseases and Therapy*, **2015**, 4, 519-28	6.2	8
54	Increased bacterial resistance: PROTEKT US--an update. *Annals of Pharmacotherapy*, **2004**, 38, S8-S13	2.9	8
53	Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient. *Journal of Pediatric Pharmacology and Therapeutics*, **2014**, 19, 135-40	1.6	8
52	The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA-Salvaging the Gold Standards with Combination Therapy. *Antibiotics*, **2020**, 9,	4.9	8
51	Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant and. *Open Forum Infectious Diseases*, **2021**, 8, ofab371	1	8

50	Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of in a Pharmacokinetic/Pharmacodynamic Model. *Antibiotics*, **2020**, 9,	4.9	7
49	Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus. *Infectious Diseases and Therapy*, **2016**, 5, 367-77	6.2	7
48	-Lactamase Inhibitors Enhance the Synergy between -Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	7
47	Global Antimicrobial Stewardship: Challenges and Successes from Frontline Stewards. *Infectious Diseases and Therapy*, **2015**, 4, 1-3	6.2	7
46	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin. *Open Forum Infectious Diseases*, **2019**, 6, ofz077	1	6
45	Combinations of (lipo)glycopeptides with -lactams against MRSA: susceptibility insights. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2894-2901	5.1	6
44	Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam. *Infectious Diseases and Therapy*, **2020**, 9, 291-304	6.2	6
43	Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections. *Infectious Diseases and Therapy*, **2018**, 7, 161-169	6.2	6
42	Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. *Infectious Diseases and Therapy*, **2019**, 8, 627-640	6.2	6
41	Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa.. *Infectious Diseases and Therapy*, **2022**, 11, 661	6.2	6
40	Comparison of clinical outcomes and risk factors in polymicrobial versus monomicrobial enterococcal bloodstream infections. *American Journal of Infection Control*, **2016**, 44, 917-21	3.8	6
39	Impact of Daptomycin Dose Exposure Alone or in Combination with -Lactams or Rifampin against Vancomycin-Resistant Enterococci in an Biofilm Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	6
38	Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 3529-3531	5.1	6
37	Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0264620	5.9	6
36	Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis in an Simulated Endocarditis Vegetation Model. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	5
35	Novel application of published risk factors for methicillin-resistant S. aureus in acute bacterial skin and skin structure infections. *International Journal of Antimicrobial Agents*, **2018**, 51, 43-46	14.3	5
34	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. *International Journal of Antimicrobial Agents*, **2019**, 54, 346-350	14.3	5
33	Genomic characterization of an extensively drug-resistant KPC-2-producing Klebsiella pneumoniae ST855 (CC258) only susceptible to ceftazidime-avibactam isolated in Brazil. *Diagnostic Microbiology and Infectious Disease*, **2017**, 89, 324-327	2.9	5

32	Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria. *Expert Opinion on Emerging Drugs*, **2001**, 6, 43-55		5
31	Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an Pharmacokinetic/Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	5
30	Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an Biofilm Model. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	5
29	Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.. *Open Forum Infectious Diseases*, **2021**, 8, ofab554	1	5
28	Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	4
27	A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli. *European Journal of Clinical Microbiology and Infectious Diseases*, **2020**, 39, 2199-2203	5.3	4
26	Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections. *Clinical Infectious Diseases*, **2021**, 73, e4560-e4567	11.6	4
25	In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant. *Antibiotics*, **2021**, 10,	4.9	4
24	Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections : Bacteriophage-Antibiotic Combination.. *Microbiology Spectrum*, **2022**, e0041122	8.9	4
23	Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection versus illusion?. *American Journal of Infection Control*, **2016**, 44, 47-9	3.8	3
22	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant. *Pharmaceutics*, **2021**, 13,	6.4	3
21	Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections. *Infectious Diseases and Therapy*, **2019**, 8, 229-242	6.2	3
20	A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia. *European Journal of Clinical Microbiology and Infectious Diseases*, **2019**, 38, 843-850	5.3	2
19	Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium. *Journal of Infectious Diseases*, **2020**, 222, 1531-1539	7	2
18	Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. *International Journal of Antimicrobial Agents*, **2020**, 55, 105970	14.3	2
17	Evaluation of Bacteriophage Cocktails Alone and in Combination with Daptomycin Against Daptomycin-Nonsusceptible. *Antimicrobial Agents and Chemotherapy*, **2021**, AAC0162321	5.9	2
16	Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2486-2488	5.1	2
15	Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Bacteremia: STAPH Study. *Open Forum Infectious Diseases*, **2021**, 8, ofab261	1	2

List of Publications

14	Impact of COVID-19 pandemic on training of pharmacy residents and fellows: Results from a national survey of postgraduate pharmacy trainees. *American Journal of Health-System Pharmacy*, **2021**, 78, 1104-1111	2.2	2
13	Exebacase in Addition to Daptomycin against MRSA. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0012821	5.9	2
12	Reply to Koehler et al. *Clinical Infectious Diseases*, **2019**, 69, 901-902	11.6	1
11	Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 1272-3	5.1	1
10	Questions on Vancomycin Dosing. *Clinical Infectious Diseases*, **2021**, 73, e1777-e1778	11.6	1
9	Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. *Infectious Diseases and Therapy*, **2019**, 8, 75-85	6.2	1
8	How to Harness the Power of Social Media for Quality Drug Information in Infectious Diseases: Perspectives on Behalf of the Society of Infectious Diseases Pharmacists.. *Clinical Infectious Diseases*, **2022**, 74, e23-e33	11.6	1
7	Novel Combination Therapy for Extensively Drug-Resistant Necrotizing Pneumonia Complicated by Empyema: A Case Report.. *Open Forum Infectious Diseases*, **2022**, 9, ofac092	1	1
6	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Bloodstream Infection.. *Open Forum Infectious Diseases*, **2022**, 9, ofab606	1	1
5	Reply to Cheng and Chuang. *Clinical Infectious Diseases*, **2019**, 69, 903-904	11.6	0
4	Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19.. *Infectious Diseases and Therapy*, **2022**, 1	6.2	0
3	Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.. *Infectious Diseases and Therapy*, **2022**, 1	6.2	0
2	Letter from the editor. *Infectious Diseases and Therapy*, **2013**, 2, 81-2	6.2	
1	Reply to Cataldo et al. *Clinical Infectious Diseases*, **2011**, 53, 310-310	11.6	